As one of the leading pharmaceutical companies in the world, the German STADA, and Serbian Hemofarm as its part, have chosen a new path of growth, with the aim of strengthening their position in existing markets and winning new ones on all continents.
The excellent operating results of STADA, enable an agreement with one of the most respected strategic partners for development, a consortium of Bain Capital and Cinven following the global trend of enlarging the model of capital acquisitions. The achieved price is 5,318 billion, and agreement reached is the best and in terms of the future STADA and its employees. STADA has recently celebrated a decade of successful business in Serbia, and investments in excess of 200 million euros, which has raised the Serbian Hemofarmto the level of a regional leader and a regional centr for South East Europe. Ambitious plans for further development of STADA promise the new opportunity and growth for Serbian Hemofarm.